| Schedule of Reportable Segment Net Loss, Including Significant Expense Categories, Attributable to Company's Reportable Segment |
The following table presents reportable segment net loss, including significant expense categories, attributable to the Company's reportable segment for the three and six months ended June 30, 2025 and 2024.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Collaboration agreements |
|
$ |
250 |
|
|
$ |
1,073 |
|
|
$ |
250 |
|
|
$ |
53,477 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Discovery costs |
|
|
|
|
|
|
|
|
|
|
|
|
Direct external costs |
|
|
259 |
|
|
|
1,398 |
|
|
|
957 |
|
|
|
3,124 |
|
Laboratory supplies and research materials |
|
|
90 |
|
|
|
959 |
|
|
|
344 |
|
|
|
1,957 |
|
Personnel related costs |
|
|
243 |
|
|
|
3,232 |
|
|
|
1,750 |
|
|
|
6,418 |
|
Facilities related costs |
|
|
145 |
|
|
|
393 |
|
|
|
503 |
|
|
|
798 |
|
Other costs |
|
|
65 |
|
|
|
842 |
|
|
|
643 |
|
|
|
1,754 |
|
Development costs |
|
|
|
|
|
|
|
|
|
|
|
|
Direct external costs |
|
|
|
|
|
|
|
|
|
|
|
|
Camonsertib program |
|
|
1,848 |
|
|
|
3,961 |
|
|
|
4,114 |
|
|
|
7,941 |
|
Lunresertib program |
|
|
3,999 |
|
|
|
7,660 |
|
|
|
8,274 |
|
|
|
15,767 |
|
RP-1664 program |
|
|
1,579 |
|
|
|
1,412 |
|
|
|
2,921 |
|
|
|
3,008 |
|
RP-3467 and Polθ program |
|
|
1,541 |
|
|
|
773 |
|
|
|
2,638 |
|
|
|
2,328 |
|
Personnel related costs |
|
|
5,070 |
|
|
|
9,186 |
|
|
|
13,233 |
|
|
|
18,845 |
|
Facilities related costs |
|
|
233 |
|
|
|
213 |
|
|
|
480 |
|
|
|
421 |
|
Other costs |
|
|
695 |
|
|
|
1,186 |
|
|
|
1,584 |
|
|
|
2,618 |
|
Debiopharm development cost reimbursement |
|
|
(1,413 |
) |
|
|
(880 |
) |
|
|
(2,682 |
) |
|
|
(1,380 |
) |
R&D tax credits |
|
|
(71 |
) |
|
|
(260 |
) |
|
|
(206 |
) |
|
|
(554 |
) |
Total research and development costs |
|
$ |
14,283 |
|
|
$ |
30,075 |
|
|
$ |
34,553 |
|
|
$ |
63,045 |
|
Personnel related costs |
|
|
2,944 |
|
|
|
5,220 |
|
|
|
7,522 |
|
|
|
10,939 |
|
Other general administrative costs (1) |
|
|
3,085 |
|
|
|
3,097 |
|
|
|
6,159 |
|
|
|
5,996 |
|
Total general and administrative costs |
|
$ |
6,029 |
|
|
$ |
8,317 |
|
|
$ |
13,681 |
|
|
$ |
16,935 |
|
Restructuring costs |
|
|
3,384 |
|
|
|
— |
|
|
|
6,649 |
|
|
|
— |
|
Total operating expenses |
|
$ |
23,696 |
|
|
$ |
38,392 |
|
|
$ |
54,883 |
|
|
$ |
79,980 |
|
Gain on sale of technology and other assets |
|
|
5,666 |
|
|
|
— |
|
|
|
5,666 |
|
|
|
— |
|
Loss from operations |
|
$ |
(17,780 |
) |
|
$ |
(37,319 |
) |
|
$ |
(48,967 |
) |
|
$ |
(26,503 |
) |
Other income, net (2) |
|
|
1,284 |
|
|
|
2,871 |
|
|
|
2,798 |
|
|
|
5,846 |
|
Income tax expense |
|
|
(248 |
) |
|
|
(326 |
) |
|
|
(618 |
) |
|
|
(955 |
) |
Net loss |
|
$ |
(16,744 |
) |
|
$ |
(34,774 |
) |
|
$ |
(46,787 |
) |
|
$ |
(21,612 |
) |
(1) Includes professional fees, directors and officers insurance costs, public company operating costs, information technology related costs, and other administrative costs. (2) Includes interest income and other expenses.
|
| Schedule of Property and Equipment, Net and Right-of-Use Assets by Location |
The Company’s property and equipment, net by country of domicile (Canada) and its subsidiary in the United States are as follows:
|
|
|
|
|
|
|
|
|
|
|
As of
June 30, |
|
|
As of
December 31, |
|
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
Canada |
|
$ |
— |
|
|
$ |
2,143 |
|
United States |
|
|
72 |
|
|
|
151 |
|
Total property and equipment, net |
|
$ |
72 |
|
|
$ |
2,294 |
|
The Company’s right-of-use assets by country of domicile (Canada) and its subsidiary in the United States are as follows:
|
|
|
|
|
|
|
|
|
|
|
As of
June 30, |
|
|
As of
December 31, |
|
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
Canada |
|
$ |
58 |
|
|
$ |
891 |
|
United States |
|
|
571 |
|
|
|
1,033 |
|
Total right-of-use assets, net |
|
$ |
629 |
|
|
$ |
1,924 |
|
|